Cleerly COMPARE
Enabling physicians to track disease progression over time, driving more informed treatment strategies
Learn More >
AI-Powered Cardiac Insights
Traditional cardiac assessments often miss the underlying disease by focusing solely on symptoms and risk factors. Cleerly changes that with our AI-driven analysis of 3D coronary computed tomography angiography (CCTA) imaging, delivering precise, comprehensive heart health insights. By reducing uncertainty and empowering healthcare professionals (HCPs) with data-driven confidence, we’re redefining the future of cardiac care.
Precision You Can Trust for Confident Decision-Making
Cleerly combines advanced AI with human expertise, utilizing millions of images from from landmark multi-center trials to inform our analysis. Our AI-driven technology delivers unparalleled accuracy and consistency to detect and analyze plaque, ischemia, and stenosis, empowering confident conversations and decision-making.
See the Cause of Coronary Artery Disease
Cleerly equips healthcare providers with precise and comprehensive heart insights. Clear, intuitive images, directly from the CCTA scan, help you understand the state of disease and treat with confidence.
Visualize, Analyze, Act
Cleerly delivers actionable insights, helping physicians assess CAD without potentially unnecessary, invasive procedures.
Comparable vs. invasive gold standards
More accurate than available non-invasive imaging tests
More accurate than CCTA alone
Book Your Demo
Healthcare professionals schedule a demo and step into the new era of personalized cardiac care.
Schedule Now
Find Cleerly Near You
Locate a facility near you offering Cleerly’s advanced technology.
See Our Locations
"For years I sought a method to quantify the density of every pixel in a coronary angiogram. When Jim Min showed me Cleerly, I was amazed. I thought, ‘This is what I’ve been looking for.’ I started using it in my patients, and it totally fulfilled the initial promise."
Dr. Arthur Agatston, MD, FACC
Chief Executive Officer, The Agatston Center
"The Cleerly method for looking at a CTA provides more information than almost any other CTAs. We're able to look at different aspects of the vessel that would change the way we treat it. I think this makes Cleerly’s product a potential game-changer. "
Dr. Morton J. Kern, , MD, MSCAI, FACC, FAHA
Professor of Medicine, University of California at Irvine
"TRANSFORM and TRANSCEND are talking about changing the entire paradigm of how we think about cardiovascular prevention. It's not about risk factors. It's about detecting disease and treating disease, and treating disease in a staged way the same way we would for cancer."
Marc Bonaca, MD, MPH
Executive Director, CPC Clinical Research
When You Think of Heart Attack Prevention,
Think 
Schedule a demo to see how Cleerly’s AI-driven insights can enhance your workflow, enabling early identification of individuals at risk of heart attack—before it happens and while the disease can be effectively managed.